Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacincaptad Pegol OLE in Geographic Atrophy
NCT05536297Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2022
- Primary completion
- Apr 2025
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of avacincaptad pegol in geographic atrophy (GA) and age-related macular degeneration (AMD), sponsored by Astellas Pharma. Primary endpoint: Number of Participants With Adverse Events at 18 months. Started Sep 2022; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05536297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536297.